Affiliation:
1. Central State Medical Academy of the Administrative Department of the President of Russia
Abstract
Xerosis is one of the most common dermatological side effects of anticancer drug therapy. The present observational study included 34 patients, among them 19 women, 15 men, mean age was 37.9 ± 3.5 years. All patients had skin xerosis, as well as various class-specific skin toxic reactions for drugs from the EGFR group (acne-like rash, paronychia, and others). With regard to skin toxic reactions, a thorough assessment of the severity was carried out and adequate therapy was prescribed in accordance with Russian clinical guidelines. In order to stop xerosis, all patients were recommended Lipikar Baume AP+М, Lipikar Syndet AP+, Cicaplast Baume B 5, Anthelios Invisible Fluid on an ongoing basis. As a result of observation (8 weeks), all patients noted the excellent organoleptic properties of La Roche-Posay products and the comfort of their use. All patients managed to control xerosis and other skin toxic reactions), none of the patients required dose reduction or withdrawal of anticancer therapy.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference18 articles.
1. Tryakin A. A., Besova N. S., Volkov N. M., Gladkov O. A., Karaseva V. V., Sakaeva D. D. et al. Practical recommendations on the general principles of anticancer drug therapy. Malignant tumors: Practical guidelines RUSSCO #3s2, 2022 (vol. 12). 27–40.
2. About MASCC [Электронный ресурс] MASCC. Режим доступа: https://www.mascc.org/about-mascc
3. Korolyova I. A., Bolotina L. V., Gladkov O. A., et al. Practical recommendations for drug treatment of dermatological reactions in patients receiving anticancer drug therapy. Malignant Tumors: Practice Guidelines RUSSCO #3s2, 2020 (vol. 10). 42.
4. Çelik U, Aydemir EH, Engin B, Oba MÇ, Yılmaz M, Meşe ŞG. Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration. J Oncol Pharm Pract. 2021; 27 (8): 1853–1860. DOI: 10.1177/1078155220970621.
5. Wollenberg A. Hautreaktionen unter EGFR-Inhibitoren-Klinik und Management. A. Wollenberg, J. Kroth, A. Hauschild [et al.] DMW-Deutsche Medizinische Wochenschrift. 2010. Vol. 135, № 04. P. 149–154. DOI: 10.1055/s-0029–1244831.